{
  "id": 7374314,
  "title": "BioNTech says CTLA-4 drug nearly doubled survival times for lung cancer",
  "url": "https://urgent.news/2026/09/14/biontech-says-ctla-4-drug-nearly-doubled-survival-times-for-lung",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-14T18:27:25.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/biontech-says-ctla-4-drug-nearly-doubled-survival-times-for-lung-cancer/"
  },
  "original_language": "en",
  "account": null,
  "summary": "BioNTech delivered a compelling piece of evidence Monday supporting the development of its CTLA-4 antibody gotistobart in lung cancer. Previously treated lung cancer patients who received the CTLA-4 antibody lived for 8.5 months longer than ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}